Headlines about DarioHealth (NASDAQ:DRIO) have been trending somewhat negative on Saturday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. DarioHealth earned a news impact score of -0.04 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 49.0371428971947 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Separately, ValuEngine upgraded shares of DarioHealth from a “hold” rating to a “buy” rating in a report on Wednesday, July 4th.
NASDAQ:DRIO traded up $0.07 during trading hours on Friday, reaching $0.99. 34,328 shares of the company’s stock were exchanged, compared to its average volume of 41,908. DarioHealth has a 12 month low of $0.89 and a 12 month high of $3.64.
DarioHealth (NASDAQ:DRIO) last issued its earnings results on Thursday, August 9th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.14). The business had revenue of $2.06 million for the quarter. DarioHealth had a negative return on equity of 443.39% and a negative net margin of 353.28%.
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.
Featured Article: What is a Tariff?
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.